According to a new report published by
Allied Market Research, titled, Transcatheter Mitral Valve Repair and Replacement
Market by Product and Indication: Global Opportunity Analysis and
Industry Forecast, 2017-2023, the tanscatheter mitral
valve repair & replacement market was valued at $324 million (excluding the
revenue from replacement valves) in 2016, and is expected to reach at $1,878
million (both repair and replacement valves) by 2023, registering a CAGR of 30.0%
from 2017 to 2023. The mechanical valves segment accounted for maximum share of
the total market in 2016.
Click Here
To Access Free Sample Report: https://www.alliedmarketresearch.com/request-sample/4512
Mitral valve is a valve in the heart that
lets the blood flow from one chamber of the heart to the left atrium, to
another valve called the left ventricle. Mitral valves help keep the blood flow
in a proper direction and avoid blood from flowing backwards. The repair and
replacement of the valves is performed when they do not supply enough blood to
the left ventricle, which further results in bacterial endocarditis, congestive
heart failure, and even sudden death.
Growth in geriatric population and rise in
mitral valve disorders drive the market growth. In addition, technological
advancements coupled with the introduction novel mitral valves are the other
factors that drive the market growth. The major restraint observed for this
market is the strict regulations by the governing bodies as well as high cost
of mitral valve surgeries and high risk associated with these procedures.
Moreover, rise in healthcare expenditure and emergence in developing countries
will create lucrative opportunities for key market players
Mitral valve Stenosis application is
anticipated to maintain its dominance during the forecast period, owing to the
high prevalence of mitral valve stenosis caused by the rheumatic fever, which
is an infectious heart disease. This has led to the remarkable demand for the
tanscatheter mitral valve repair & replacement devices.
Key Findings of
theTranscatheter Mitral Valve Repair and Replacement Market
- The U.S. was the major shareholder in the
North America transcatheter mitral valve repair & replacement market,
and accounted for the highest share in 2016.
- Bioprosthetic tissue (biological) valves
is expected to grow at the significant CAGR of 30.5% during 2017-2023.
- China occupied about one-fourth share of
the total Asia-Pacific transcatheter mitral valve repair & replacement
market in 2016. Whereas, India is expected to grow rapidly registering a
CAGR of 32.9% during the forecast period.
- The mitral valve regurgitation segment is
growing at a highest CAGR of 33.5% from 2017 to 2023.
- UK is anticipated to exhibit a highest
CAGR during the forecast period.
For
Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/4512
In 2016, Asia-Pacific and LAMEA collectively
accounted for about one-third share of the global transcatheter mitral valve
repair & replacement market and is expected to continue this trend
throughout the forecast period. Key factors driving the market include the
prevalence of mitral valve diseases and deaths caused owing to this disease.
Mitral valve diseases are sometimes inoperable and can be treated by performing
mitral valve surgeries.
The report provides a comprehensive analysis
of the key players operating in the global transcatheter mitral valve repair
& replacement market such as LivaNova Plc, Abbott Laboratories, Biotronik
Pvt Ltd, Edward Lifesciences, Medtronic Plc, Neovasc Inc., NeoChord, St. Jude
Medical, Direct Flow Medical Inc. and Colibri Heart Valve, LLC.
The other players in the value chain of the
global transcatheter mitral valve repair and replacement market include Venus
Medtech, HLT Medical, Transcatheter Technologies GmbH, MValve Technologies,
Coramaze Technologies GmbH, and Mardil Medical.
No comments:
Post a Comment